辰欣药业
(603367)
| 流通市值：60.08亿 | | | 总市值：60.08亿 |
| 流通股本：4.53亿 | | | 总股本：4.53亿 |
| 利润表 |
| 报告期 | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
| 营业总收入 | 2,475,322,404.18 | 1,693,162,287.42 | 850,351,441.43 | 3,444,716,683.93 |
| 营业总成本 | 2,153,057,857.69 | 1,499,927,455.65 | 690,429,639.56 | 3,089,204,509.21 |
| 其他经营收益 | | | | |
| 营业利润 | 378,099,940.63 | 285,419,644.91 | 144,246,680.59 | 499,881,818.61 |
| 利润总额 | 378,249,825.21 | 285,301,527.1 | 143,854,042.99 | 496,194,690.13 |
| 净利润 | 350,763,422.21 | 266,953,312.48 | 132,112,004.57 | 425,618,864.59 |
| 每股收益 | | | | |
| 其他综合收益 | -1,278,277.75 | -1,278,277.75 | 21,033.62 | 58,501.11 |
| 综合收益总额 | 349,485,144.46 | 265,675,034.73 | 132,133,038.19 | 425,677,365.7 |
| 资产负债表 |
| 报告期 | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
| 流动资产: | | | | |
| 流动资产合计 | 5,746,351,274.09 | 5,786,805,134 | 5,415,948,983.27 | 5,210,179,358.71 |
| 非流动资产: | | | | |
| 非流动资产合计 | 1,993,270,515.61 | 2,048,023,773.43 | 2,240,045,091.65 | 2,387,288,100.33 |
| 资产总计 | 7,739,621,789.7 | 7,834,828,907.43 | 7,655,994,074.92 | 7,597,467,459.04 |
| 流动负债: | | | | |
| 流动负债合计 | 1,215,060,604.12 | 1,276,973,552.47 | 1,164,225,433.83 | 1,223,779,367.78 |
| 非流动负债: | | | | |
| 非流动负债合计 | 114,699,248.17 | 134,008,635.41 | 128,931,859.24 | 142,984,347.1 |
| 负债合计 | 1,329,759,852.29 | 1,410,982,187.88 | 1,293,157,293.07 | 1,366,763,714.88 |
| 所有者权益(或股东权益): | | | | |
| 归属于母公司股东权益合计 | 6,367,419,016.46 | 6,381,804,234.91 | 6,321,950,519.07 | 6,191,184,283.25 |
| 股东权益合计 | 6,409,861,937.41 | 6,423,846,719.55 | 6,362,836,781.85 | 6,230,703,744.16 |
| 负债和股东权益合计 | 7,739,621,789.7 | 7,834,828,907.43 | 7,655,994,074.92 | 7,597,467,459.04 |
| 现金流量表 |
| 报告期 | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
| 经营活动产生的现金流量: | | | | |
| 经营活动现金流入小计 | 2,531,154,321.36 | 1,711,642,107.12 | 827,102,097.28 | 3,368,097,453.25 |
| 经营活动现金流出小计 | 1,965,340,934.98 | 1,284,508,782.19 | 634,565,119.54 | 2,901,722,870.75 |
| 经营活动产生的现金流量净额 | 565,813,386.38 | 427,133,324.93 | 192,536,977.74 | 466,374,582.5 |
| 投资活动产生的现金流量: | | | | |
| 投资活动现金流入小计 | 5,853,599,161.03 | 3,240,439,235.38 | 1,255,730,811.04 | 1,515,907,319.24 |
| 投资活动现金流出小计 | 6,236,190,695.65 | 3,384,023,460.25 | 1,802,906,277.87 | 1,689,727,864.02 |
| 投资活动产生的现金流量净额 | -382,591,534.62 | -143,584,224.87 | -547,175,466.83 | -173,820,544.78 |
| 筹资活动产生的现金流量: | | | | |
| 筹资活动现金流入小计 | -44,996,554.68 | - | - | 27,428,633.11 |
| 筹资活动现金流出小计 | 225,892,145.22 | 83,580,003.97 | 2,182,950.31 | 259,388,761.47 |
| 筹资活动产生的现金流量净额 | -270,888,699.9 | -83,580,003.97 | -2,182,950.31 | -231,960,128.36 |
| 汇率变动对现金及现金等价物的影响 | -4,616,391.15 | -3,337,736.34 | -1,416,275.05 | -793,399.29 |
| 现金及现金等价物净增加额 | -92,283,239.29 | 196,631,359.75 | -358,237,714.45 | 59,800,510.07 |
| 期末现金及现金等价物余额 | 1,119,792,493.58 | 1,408,707,092.62 | 853,838,018.42 | 1,180,273,813.96 |
| 补充资料: | | | | |
| 现金及现金等价物的净增加额 | - | 196,631,359.75 | - | 59,800,510.07 |